UK Markets closed

Global Primary Immunodeficiency Therapeutics Market to Reach $10.4 Billion by 2027

ReportLinker
ReportLinker

Abstract: What’s New for 2022? Global competitiveness and key competitor percentage market shares. Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Primary Immunodeficiency Therapeutics Industry" - https://www.reportlinker.com/p06361486/?utm_source=GNW
Online interactive peer-to-peer collaborative bespoke updates
Access to our digital archives and MarketGlass Research Platform
Complimentary updates for one year

Global Primary Immunodeficiency Therapeutics Market to Reach $10.4 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Primary Immunodeficiency Therapeutics estimated at US$6.7 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 6.4% over the analysis period 2020-2027. Antibody Deficiency, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$6.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cellular Immunodeficiency segment is readjusted to a revised 5.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 5.9% CAGR

The Primary Immunodeficiency Therapeutics market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2027 trailing a CAGR of 5.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Innate Immune Disorders Segment to Record 6.2% CAGR

In the global Innate Immune Disorders segment, USA, Canada, Japan, China and Europe will drive the 6.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$669.8 Million in the year 2020 will reach a projected size of US$1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 47 Featured) -
CSL Behring
Grifols International SA


Read the full report: https://www.reportlinker.com/p06361486/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Primary Immunodeficiency Diseases - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Primary Immunodeficiency Therapeutics Market
Analysis of Annual Sales in US$ Million for Years 2012 through
2027

Table 2: World Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 3: World Historic Review for Primary Immunodeficiency
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 4: World 15-Year Perspective for Primary Immunodeficiency
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2012, 2021 & 2027

Table 5: World Recent Past, Current & Future Analysis for
Antibody Deficiency by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 6: World Historic Review for Antibody Deficiency by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 7: World 15-Year Perspective for Antibody Deficiency by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 8: World Recent Past, Current & Future Analysis for
Cellular Immunodeficiency by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 9: World Historic Review for Cellular Immunodeficiency by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 10: World 15-Year Perspective for Cellular
Immunodeficiency by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2021 & 2027

Table 11: World Recent Past, Current & Future Analysis for
Innate Immune Disorders by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 12: World Historic Review for Innate Immune Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 13: World 15-Year Perspective for Innate Immune Disorders
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 14: World Recent Past, Current & Future Analysis for
Immunoglobuline Replacement Therapy by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 15: World Historic Review for Immunoglobuline Replacement
Therapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 16: World 15-Year Perspective for Immunoglobuline
Replacement Therapy by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 17: World Recent Past, Current & Future Analysis for
Antibiotic Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 18: World Historic Review for Antibiotic Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 19: World 15-Year Perspective for Antibiotic Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 20: World Recent Past, Current & Future Analysis for Stem
Cell & Gene Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 21: World Historic Review for Stem Cell & Gene Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 22: World 15-Year Perspective for Stem Cell & Gene
Therapy by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2021 & 2027

Table 23: World Recent Past, Current & Future Analysis for
Other Treatment Types by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 24: World Historic Review for Other Treatment Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 25: World 15-Year Perspective for Other Treatment Types
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2022 (E)
Table 26: USA Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 27: USA Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 28: USA 15-Year Perspective for Primary Immunodeficiency
Therapeutics by Disease Type - Percentage Breakdown of Value
Sales for Antibody Deficiency, Cellular Immunodeficiency and
Innate Immune Disorders for the Years 2012, 2021 & 2027

Table 29: USA Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 30: USA Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 31: USA 15-Year Perspective for Primary Immunodeficiency
Therapeutics by Treatment Type - Percentage Breakdown of Value
Sales for Immunoglobuline Replacement Therapy, Antibiotic
Therapy, Stem Cell & Gene Therapy and Other Treatment Types for
the Years 2012, 2021 & 2027

CANADA
Table 32: Canada Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 33: Canada Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 34: Canada 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 35: Canada Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 36: Canada Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 37: Canada 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

JAPAN
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 38: Japan Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 39: Japan Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 40: Japan 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 41: Japan Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 42: Japan Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 43: Japan 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

CHINA
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Table 44: China Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 45: China Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 46: China 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 47: China Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 48: China Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 49: China 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

EUROPE
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 50: Europe Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 51: Europe Historic Review for Primary Immunodeficiency
Therapeutics by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 52: Europe 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2012, 2021 & 2027

Table 53: Europe Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 54: Europe Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 55: Europe 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 56: Europe Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 57: Europe Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 58: Europe 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

FRANCE
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2022 (E)
Table 59: France Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 60: France Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 61: France 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 62: France Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 63: France Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 64: France 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

GERMANY
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2022:
( E)
Table 65: Germany Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 66: Germany Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 67: Germany 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 68: Germany Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 69: Germany Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 70: Germany 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

ITALY
Table 71: Italy Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 72: Italy Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 73: Italy 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 74: Italy Recent Past, Current & Future Analysis for
Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 75: Italy Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 76: Italy 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

UNITED KINGDOM
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2022 (E)
Table 77: UK Recent Past, Current & Future Analysis for Primary
Immunodeficiency Therapeutics by Disease Type - Antibody
Deficiency, Cellular Immunodeficiency and Innate Immune
Disorders - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 78: UK Historic Review for Primary Immunodeficiency
Therapeutics by Disease Type - Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 79: UK 15-Year Perspective for Primary Immunodeficiency
Therapeutics by Disease Type - Percentage Breakdown of Value
Sales for Antibody Deficiency, Cellular Immunodeficiency and
Innate Immune Disorders for the Years 2012, 2021 & 2027

Table 80: UK Recent Past, Current & Future Analysis for Primary
Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 81: UK Historic Review for Primary Immunodeficiency
Therapeutics by Treatment Type - Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 82: UK 15-Year Perspective for Primary Immunodeficiency
Therapeutics by Treatment Type - Percentage Breakdown of Value
Sales for Immunoglobuline Replacement Therapy, Antibiotic
Therapy, Stem Cell & Gene Therapy and Other Treatment Types for
the Years 2012, 2021 & 2027

REST OF EUROPE
Table 83: Rest of Europe Recent Past, Current & Future Analysis
for Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 84: Rest of Europe Historic Review for Primary
Immunodeficiency Therapeutics by Disease Type - Antibody
Deficiency, Cellular Immunodeficiency and Innate Immune
Disorders Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 85: Rest of Europe 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 86: Rest of Europe Recent Past, Current & Future Analysis
for Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 87: Rest of Europe Historic Review for Primary
Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 88: Rest of Europe 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

ASIA-PACIFIC
Primary Immunodeficiency Therapeutics Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Asia-Pacific for
2022 (E)
Table 89: Asia-Pacific Recent Past, Current & Future Analysis
for Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 90: Asia-Pacific Historic Review for Primary
Immunodeficiency Therapeutics by Disease Type - Antibody
Deficiency, Cellular Immunodeficiency and Innate Immune
Disorders Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 91: Asia-Pacific 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 92: Asia-Pacific Recent Past, Current & Future Analysis
for Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 93: Asia-Pacific Historic Review for Primary
Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 94: Asia-Pacific 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

REST OF WORLD
Table 95: Rest of World Recent Past, Current & Future Analysis
for Primary Immunodeficiency Therapeutics by Disease Type -
Antibody Deficiency, Cellular Immunodeficiency and Innate
Immune Disorders - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 96: Rest of World Historic Review for Primary
Immunodeficiency Therapeutics by Disease Type - Antibody
Deficiency, Cellular Immunodeficiency and Innate Immune
Disorders Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 97: Rest of World 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Disease Type - Percentage
Breakdown of Value Sales for Antibody Deficiency, Cellular
Immunodeficiency and Innate Immune Disorders for the Years
2012, 2021 & 2027

Table 98: Rest of World Recent Past, Current & Future Analysis
for Primary Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 99: Rest of World Historic Review for Primary
Immunodeficiency Therapeutics by Treatment Type -
Immunoglobuline Replacement Therapy, Antibiotic Therapy, Stem
Cell & Gene Therapy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 100: Rest of World 15-Year Perspective for Primary
Immunodeficiency Therapeutics by Treatment Type - Percentage
Breakdown of Value Sales for Immunoglobuline Replacement
Therapy, Antibiotic Therapy, Stem Cell & Gene Therapy and Other
Treatment Types for the Years 2012, 2021 & 2027

IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06361486/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001